Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma

Leukemia. 2005 Jan;19(1):154-6. doi: 10.1038/sj.leu.2403541.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Agents, Alkylating / administration & dosage*
  • Antineoplastic Agents, Alkylating / adverse effects
  • Arsenic Trioxide
  • Arsenicals / administration & dosage*
  • Arsenicals / adverse effects
  • Ascorbic Acid / administration & dosage*
  • Ascorbic Acid / adverse effects
  • Female
  • Humans
  • Male
  • Melphalan / administration & dosage*
  • Melphalan / adverse effects
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Oxides / administration & dosage*
  • Oxides / adverse effects
  • Recurrence
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Alkylating
  • Arsenicals
  • Oxides
  • Ascorbic Acid
  • Melphalan
  • Arsenic Trioxide